Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors

Clinical trial NCT05914376 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05914376
Sponsor: Hangzhou Converd Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors

Start date: 2023-07-05
Primary completion: 2025-07-02
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.